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Abstract: A series of alkyl- and aryl-1,2,4-triazino[4,3-c]quinazolines (5a-h and 8a-h) were synthesized and character-
ized. The title compounds were evaluated for their in vivo bronchodilator activity on guinea pigs. All the test compounds 
exhibited good protection against histamine-induced bronchospasm. The structure-activity relationships based on the re-
sults obtained for these series were studied. Incorporation of an aryl ring with halo substitution to the theophylline bioisos-
tere increases its potency. Among the compounds tested, 5b was found to be the most potent with 88.7% protection 
against histamine-induced bronchospasm compared to the standard compound aminophylline (87.8%). 
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INTRODUCTION 
  Bronchial asthma is a chronic debilitating disease; in 
severe forms, it can even be life-threatening. It is, in general 
characterized by both bronchoconstriction and airway in-
flammation which leads to a bronchial hyperresponsiveness 
[1]. Despite a narrow therapeutic index, methylxanthines are 
the drugs of choice in asthma therapy. 
  Currently new tricyclic heterocyclic compounds designed 
on the basis of xanthine skeleton are being investigated with 
hopes of discovering bronchodilators with a wider margin of 
safety. While reviewing the recent perspectives in the design 
of antiasthmatic agents [2], we observed that different angu-
larly fused heterocyclic ring systems like imidazoquinolines 
[3], imidazonaphthyridines [4], triazolothienopyrimidines 
[5], benzimidazoloquinazolines [6], imidazoquinazolines [7], 
benzimidazolopyridopyrimidines [8], imidazothienopyrimi-
dines [9]
 and triazinoquinazolines [10] are potentially useful 
compounds. Previous studies with respect to xanthine deriva-
tives suggest that an increase in the lipophilicity of the xan-
thine derivatives enhances bronchodilatory activity,   
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irrespective of its side effect profile [11]. Based on these 
observations, a hypothetical model has been proposed (Fig. 
1) with the following broad objectives: to develop xanthine-
based but non-xanthine, new fused heterocycles, capable of 
exerting bronchodilatory effects similar to theophylline, to 
increase the potency and to minimize the undesirable CNS 
and cardiovascular effects. 
  To achieve these objectives, we tried synthesizing a 
novel series of heterofused quinazolines and tested for their 
bronchodilatory activity. Hence we are herewith reporting 
the synthesis of a set of novel 6-alkyl-1,2,4-triazino[4,3-
c]quinazolines and 6-aryl-1,2,4-triazino[4,3-c]quinazolines 
as potential bronchodilators. 
MATERIAL AND METHODS 
General Methods 
  Melting points were determined in open capillaries on a 
Thermonik melting point apparatus (Mumbai, India) and 
were uncorrected. IR spectra (KBr) (max; cm
-1) were re-
corded on a Perkin Elmer spectrophotometer (577 model). 
1H-NMR spectra were recorded on Bruker WM-400 spec-
trometer (in  ppm) (Bruker, Flawil, Switzerland) using 
TMS as internal standard and mass spectra (EI-MS) on Jeol 
D-300 spectrometer at 70 eV. Elemental analyses were per-
formed on Carlo-Erba 1108 elemental analyser (Heraeus, 
Hanau, Germany). Silica gel plates (Merck, Whitehouse sta-
tion, NJ) were used to monitor the progress of the reaction, 
using chloroform-methanol as the mobile phase. All chemi-
cals and reagents used in the synthesis were obtained from 
Sigma (Sigma-Aldrich, St. Louis MO), Lancaster (Alfa Ae-
sar, Ward Hill, MA) or Spectrochem Pvt. Ltd. (Mumbai, 
India) and were used without further purification. The start-
ing material, 2-alkyl- and 2-aryl-3,1-benzoxazin-4(3H)-ones 
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  The synthesized compounds were characterized by their 
physical and spectral data and are given below. The in vivo 
bronchodilatory activity of 6-alkyl/aryl-3-oxo-[1,2,4]triazino 
[4,3-c] quinazolines is given in Table 1. 
Chemistry 
Synthesis of 2-Alkyl/Aryl-4-Oxo-3(4H)Quinazolinacetic 
Acids (2a-p) 
 The  2-alkyl/aryl-4-oxo-3(4H)-quinazolineacetic acids 
(2a-p), can be synthesized by two methods (Method A & B): 
 Method  A: The appropriate alkyl benzoxazinone (1a-h; 
0.01 mol) and glycine (0.01 mol) were ground and kept in a 
50 ml beaker. To this mixture, 1-methoxy-2-(2-methoxy-
ethoxy)ethane (2 ml) was added and the mixture was heated 
to 160-180 °C for 20-30 minutes. After the separation and 
evaporation of water from the mixture, the product was 
cooled down to 80 °C and ethanol (95%, 20 ml) was added 
through continuous trituration. The obtained product was 
filtered off and washed twice with cold ethanol (10 ml), once 
with water (50 ml), and again by ethanol (10 ml) under vac-
uum conditions. The product was dried and recrystallized 
from ethanol (95%) to yield a colorless pure product. 
 Method  B:  To the appropriate compound 3, 1-
benzoxazin-4(3H)-one (1a-h; 0.01 mol) in aqueous pyridine 
(50%), glycine (0.012 mol) was added and heated under re-
flux for 6 h. After this period, the excess pyridine was dis-
tilled off. The resulting residue was digested with hydrochlo-
ric acid (10%; 20 ml) for 2 h on a water bath. The obtained 
product was washed with small quantities of water and re-
crystallized from ethanol (95%) to yield a colorless product. 
 Sixteen  quinazolineacetic  acids  (2a-p) were prepared 
through these methods. The Rf values were obtained from 
TLCs where, a chloroform/methanol mixture (3:1 v/v) was 
used as the mobile phase for compounds 2a-h, and chloro-
form/ethyl acetate (1:1 v/v) was used as the mobile phase for 
compounds 2i-p 
 2-Methyl-4-oxo-3(4H)-quinazolineacetic acid (2a) Yield: 
Method A: 1.74 g (80%); Method B: 1.52 g (70%). mp: 260-
263 °C (d) (Lit. m.p. 260-263 °C) [14]. TLC Rf: 0.5. IR (KBr) 
cm
-1: 3416-3462 (br, COOH), 1680 (CO), 1585. MS m/z: 319 
(M
+), 326, 292, 263, 265, 253. Anal. Calcd for 
C13H13N2O2SBr: C, 60.60; H, 4.62; N, 12.8. Found: C, 60.33; 
H, 4.59; N, 12.54. 
   6-Bromo-2-methyl-4-oxo-3(4H)-quinazolineacetic acid (2b) 
Yield: 2.30 g (78%). mp: 230-234 °C. TLC Rf: 0.43. IR (KBr) 
cm
-1: 3415-3460 (br, COOH), 1681 (C=O), 1586. 
1H-NMR 
(DMSO-d6) : 2.42 (s, 3H,CH3); 4.65 (s, 2H, COCH2); 7.61 (d, 
1H, H at C-8, J = 8.1 Hz), 7.93 (dd, 1H, H at C-7, J = 8.55 
Hz, 2.18 Hz); 8.51 (d, 1H, H at C-5, J = 2.38 Hz). MS m/z: 
297 (M
+), 295, 277, 249. Anal. Calcd for C11H9N2O3Br: C, 
44.45; H, 3.05; N, 9.43. Found: C, 44.60; H, 3.22; N, 9.19. 
 6,8-Dibromo-2-methyl-4-oxo-3(4H)-quinazolineacetic acid 
(2c) Yield: 2.82 g (75%). mp: 244-246 °C (Lit. m.p. 230 °C) 
[15]. TLC Rf: 0.39. IR (KBr) cm
-1: 3414-3461 (br, COOH), 
1682 (C=O), 1584. 
1H-NMR (DMSO-d6) : 2.55 (s, 3H,CH3); 
4.58 (s, 2H, COCH2); 8.18 (s, 1H, H at C-7); 8.30 (s, H at C-
5). MS m/z: 376 (M
+), 358, 330. Anal. Calcd for 
C11H9N2O3Br: C, 35.12; H, 2.15; N, 7.45. Found: C, 35.20; H, 
2.05; N, 7.28. 
 6-Iodo-2-methyl-4-oxo-3(4H)-quinazolineacetic acid (2d) 
Yield: 2.47 g (72%). mp: 256-258 °C. TLC Rf: 0.25. IR (KBr) 
cm
-1: 3416-3460 (br, COOH), 1680 (C=O), 1585. 
1H-NMR 
(DMSO-d6) : 2.52 (s, 3H,CH3); 4.68 (s, 2H, COCH2); 7.70 (d, 
1H, H at C-8, J = 8.1 Hz), 7.98 (dd, 1H, H at C-7, J = 8.1 Hz, 
2.18 Hz); 8.42 (d, 1H, H at C-5, J = 2.2 Hz). MS m/z: 344 
(M
+), 342, 324, 296. Anal. Calcd for C11H9N2O3I: C, 38.38; H, 
2.64; N,8.14. Found: C, 38.39; H, 2.73; N, 8.30. 
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1)  Replacement of N-3 nitrogen with carbon 
2)  Substitution of aromatic ring across C-2 and C-3 so as to enhance lipophilicity 
3)  Replacement of C-5 with isosteric nitrogen and introduction of double bond across 4-9 position 
4)  Introduction of oxo/thioxo group at C-8 and halo substitutions on aromatic ring 
5)  Replacement of triazolo ring with triazino ring 
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 2-Ethyl-4-oxo-3(4H))-quinazolineacetic acid (2e) Yield: 
1.11 g (48%). mp: 225 °C (d). TLC Rf: 0.61. IR (KBr) cm
-1: 
3414-3459 (br, COOH), 1681 (C=O), 1585. 
1H-NMR (DM-
SO-d6) : 1.38-1.41 (t, 3H, -CH2CH3, J = 8.0 Hz); 2.70-2.75 
(q, 2H, CH2CH3, J = 8.0 Hz) ; 4.72 (s, 2H, COCH2); 7.70 (m, 
H at C-5,6,7,8). MS m/z: 232 (M
+), 215, 187, 159. Anal. Calcd 
for C12H12N2O3: C, 62.05; H, 5.21; N,12.07. Found: C, 61.95; 
H, 5.03; N, 11.89. 
 6-Bromo-2-ethyl-4-oxo-3(4H)-quinazolineacetic acid (2f) 
Yield: 1.61g (52%). mp: 246-248 °C. TLC Rf: 0.57. IR (KBr) 
cm
-1: 3413-3460 (br, COOH), 1678 (C=O), 1584. 
1H-NMR 
(DMSO-d6) : 1.41-1.45 (t, 3H, -CH2CH3, J = 7.8 Hz); 2.70-
2.75 (q, 2H, CH2CH3, J = 7.9 Hz) ; 4.65 (s, 2H, COCH2); 7.68 
(d, 1H, H at C-8, J = 8.3 Hz), 8.02 (dd, 1H, H at C-7, J = 8.3 
Hz, 2.2 Hz); 8.35 (d, 1H, H at C-5, J = 2.2 Hz). MS m/z: 311 
(M
+), 309, 294,266. Anal. Calcd for C12H11N2O3Br: C, 46.30; 
H, 3.57; N, 9.01. Found: C, 46.35; H, 3.38; N, 9.23. 
 6,8-Dibromo-2-ethyl-4-oxo-3(4H))-quinazolineacetic acid 
(2g) Yield: 2.14 g (55%). mp: 258-260 °C. TLC Rf: 0.5. IR 
(KBr) cm
-1: 3417-3459 (br, COOH), 1680 (C=O), 1586. 
1H-
NMR (DMSO-d6) : 1.401.42 (t, 3H, -CH2CH3, J = 8.1 Hz); 
2.70-2.75 (q, 2H, CH2CH3, J = 8.0 Hz); 4.52 (s, 2H, COCH2); 
7.8 (s, 1H, H at C-7); 8.23 (s, H at C-5). MS m/z: 390 (M
+), 
373, 345. Anal. Calcd for C12H10N2O3Br2: C, 36.93; H, 2.59; 
N, 7.18. Found: C, 37.08; H, 2.65; N, 7.32. 
 6-Iodo-2-ethyl-4-oxo-3(4H)-quinazolineacetic acid (2h) 
Yield: 1.86 g (52%). mp: 272-274 °C. TLC Rf: 0.29. IR (KBr) 
cm
-1: 3415-3460 (br, COOH), 1679 (C=O), 1585. 
1H-NMR 
(DMSO-d6) : 1.39-1.42 (t, 3H, -CH2CH3, J = 7.9 Hz); 2.67-
2.72 (q, 2H, CH2CH3, J = 7.9 Hz) ; 4.62 (s, 2H, COCH2); 7.65 
(d, 1H, H at C-8, J = 8.3 Hz), 8.05 (dd, 1H, H at C-7, J = 8.3 
Hz, 2.2 Hz); 8.38 (d, 1H, H at C-5, J = 2.2 Hz). MS m/z: 358 
(M
+), 341, 294, 313, 285. Anal. Calcd for C12H12N2O3I: C, 
40.23; H, 3.10; N, 7.82. Found: C, 40.33; H, 2.88; N, 7.83. 
 2-Phenyl-4-oxo-3(4H)-quinazolineacetic acid (2i) Yield: 
Method-A: 2.1g (75%); Method-B: 1.96 g (70%); mp: 130-
132 °C (d) (Lit. m.p. 120 °C) [16] TLC Rf: 0.56. IR (KBr) cm
-
1: 3225-3275 (br, COOH), 2930, 2610, 1686 (C=O), 1608, 
1579. 
1H-NMR (DMSO-d6) : 4.42 (s, 2H, COCH2); 7.51-7.82 
(m, 9H, Ar-H). MS m/z: 280 (M
+), 263, 235. Anal. Calcd for 
C16H12N2O3: C, 68.55; H, 4.32; N, 10.00. Found: C, 68.48; H, 
4.32; N, 9.96. 
 2-[4-Methylphenyl]-4-oxo-3(4H)-quinazolineacetic acid 
(2j) Yield: Method-A: 2.10 g (72%); Method-B: 1.08 g (37%). 
mp: 184-186 °C. TLC Rf: 0.60. IR (KBr) cm
-1: 3230-3280 (br, 
COOH), 2935, 2612, 1688 (C=O), 1605, 1578. 
1H-NMR 
(DMSO-d6) : 2.3 (s, 3H, PhCH3);  4.48 (s, 2H, COCH2); 7.45-
7.78 (m, 8H, Ar-H). MS m/z: 294 (M
+), 277, 249. Anal. Calcd 
for C17H14N2O3: C, 69.36; H, 4.80; N, 9.52. Found: C, 69.52; 
H, 4.67; N, 9.79. 
 2-[2-Methoxyphenyl]-4-oxo-3(4H)-quinazolineacetic acid 
(2k) Yield: Method-A: 2.3 g (74%); Method-B: 1.80 g (69%). 
mp: 163-165 °C (Lit. m.p. 130 °C) [17]. TLC Rf: 0.49. IR 
(KBr) cm
-1: 3228-3278 (br, COOH), 2933, 2610, 1686 (C=O), 
1604, 1575, 1260, 1034. 
1H-NMR (DMSO-d6) : 3.73 (s, 3H, 
OCH3);  4.38 (s, 2H, COCH2); 7.6-8.12 (m, 8H, Ar-H). MS 
m/z: 310 (M
+), 291, 295. Anal. Calcd for C17H14N2O4: C, 
65.79; H, 4.55; N, 9.03. Found: C, 66.03; H, 4.55; N, 8.84. 
 2-[3-Methoxyphenyl]-4-oxo-3(4H)-quinazolineacetic acid 
(2l) Yield: Method-A: 2.35 g (76%); Method-B: 2.10 g (68%). 
mp: 179-182 °C. TLC Rf: 0.53. IR (KBr) cm
-1
: 3235-3280 (br, 
COOH), 2928, 2617, 1682 (C=O), 1600, 1578, 1262, 1032. 
1H-NMR (DMSO-d6) : 3.53 (s, 3H, OCH3);  4.49 (s, 2H, CO-
CH2); 7.65-8.20 (m, 8H, Ar-H). MS m/z: 310 (M
+), 291, 295. 
Anal. Calcd for C17H14N2O4: C, 65.79; H, 4.55; N, 9.03. 
Found: C, 65.75; H, 4.65; N, 9.17. 
 2-[4-Methoxyphenyl]-4-oxo-3(4H)-quinazolineacetic acid 
(2m)  Yield: Method-A: 2.32 g (75%); Method-B: 2.07 g 
(67%). mp: 168-169 °C. TLC Rf: 0.51. IR (KBr) cm
-1: 3223-
3279 (br, COOH), 2935, 2614, 1675 (C=O), 1612, 1568, 
1225, 1025.
 1H-NMR (DMSO-d6) : 3.51 (s, 3H, OCH3);  4.53 
(s, 2H, COCH2); 7.55-7.90 (m, 8H, Ar-H). MS m/z: 310 (M
+), 
291, 295. Anal. Calcd for C17H14N2O4: C, 65.79; H, 4.55; N, 
9.03. Found: C, 65.83; H, 4.72; N, 9.21. 
 2-[4-Bromophenyl]-4-oxo-3(4H)-quinazolineacetic acid 
(2n)  Yield: Method-A: 2.58 g (72%); Method-B: 1.80 g 
(50%). mp: 177-179 °C. TLC Rf: 0.55. IR (KBr) cm
-1: 3232-
3276 (br, COOH), 2933, 2609, 1685 (C=O), 1605, 1582.
 1H-
NMR (DMSO-d6) :  4.75 (s, 2H, COCH2); 7.85-8.37 (m, 8H, 
Ar-H). MS m/z: 359 (M
+), 342. Anal. Calcd for 
C16H11N2O3Br: C, 53.48; H, 3.09; N, 7.80. Found: C, 53.50; 
H, 2.99; N, 7.88. 
 2-[4-Nitrophenyl]-4-oxo-3(4H)-quinazolineacetic acid 
(2o)  Yield: Method-A: 2.60 g (80%); Method-B: 1.85 g 
(57%). mp: 255-257 °C. TLC Rf: 0.47. IR (KBr) cm
-1: 3220-
3270 (br, COOH), 2925, 2613, 1682 (C=O), 1608, 1579, 
1486, 1322.
 1 H-NMR (DMSO-d6)  :  5.1 (s, 2H, COCH2); 
7.92-8.43 (m, 8H, Ar-H). MS m/z: 325 (M
+), 308. Anal. Calcd 
for C16H11N3O5: C, 59.06; H, 3.41; N, 12.92. Found: C, 59.19; 
H, 3.45; N, 13.17. 
 2-[3-Chlorophenyl]-4-oxo-3(4H)-quinazolineacetic acid 
(2p)  Yield: Method-A: 2.26 g (72%); Method-B: 1.64 g 
(52%). mp: 183-185 °C. TLC Rf: 0.49. IR (KBr) cm
-1: 3222-
3272 (br, COOH), 2928, 2615, 1684 (C=O), 1595, 1580.
 1H-
NMR (DMSO-d6) :  4.69 (s, 2H, COCH2); 7.75-8.13 (m, 8H, 
Ar-H). MS m/z: 314.5 (M
+). Anal. Calcd for C16H11N2O3Cl: C, 
58.44; H, 3.37; N, 12.79. Found: C, 58.51; H, 3.43; N, 12.78. 
Synthesis of 2-Alkyl-4-Oxo-3(4H)-Quinazolineacetic Acid 
Methyl Esters (3a-h) 
  Methanol (20 ml) was added to 2-alkyl-4-oxo-3(4H)-
quinazoline acetic acid (2a-h; 0.01 mol) and cooled below 20 
°C. Acetyl chloride (1.4 ml) was added to this solution drop by 
drop with constant shaking. The solution was heated under 
reflux on a water bath for one hour. Then the solution was 
concentrated in vacuo to half of its volume. When the hydro-
chloride salt began to separate, the mixture was poured onto 
50 ml of crushed ice and basified with aqueous ammonia. The 
product was removed by two extractions with chloroform. 
Evaporation of the combined extracts in vacuum yielded 3a-h. 
This product was recrystallized with benzene/hexane (2:1 v/v) 
to yield 50% of colorless crystalline product. The purity of the 104    The Open Medicinal Chemistry Journal, 2008, Volume 2  Kombu et al. 
compounds was confirmed by TLC using chloro-
form/methanol (9:1 v/v) as the mobile phase. 
 2-Methyl-4-oxo-3(4H)-quinazolineacetic acid methyl 
ester (3a) Yield: 1.5 g (65%). mp: 114-115 °C (Lit. m.p. 114-
115 °C) [18]. TLC Rf: 0.57. IR (KBr) cm
-1: 1745 (C=O), 1680 
(C=O). MS m/z: 232 (M
+). Anal. Calcd for C12H12N2O3: C, 
62.05; H, 5.21; N,12.07. Found: C, 62.19; H, 5.17; N, 12.09. 
 6-Bromo-2-methyl-4-oxo-3(4H)-quinazolineacetic acid 
methyl ester (3b) Yield: 2.43 g (78%). mp: 131-133 °C (Lit.
 
m.p. 131-133 °C) [19]. TLC Rf: 0.52. IR (KBr) cm
-1: 1742 
(C=O), 1692 (C=O). MS m/z: 311 (M
+).  Anal. Calcd for 
C12H11N2O3Br: C, 46.30; H, 3.57; N, 9.01. Found: C, 46.40; 
H, 3.59; N, 9.13. 
 6,8-Dibromo-2-methyl-4-oxo-3(4H)-quinazolineaceticacid 
methyl ester (3c) Yield: 2.9 g (74%): mp: 155 °C (d). TLC 
Rf: 0.50. IR (KBr) cm
-1: 1742 (C=O), 1692 (C=O). 
1H-NMR 
(CDCl3) : 1.63 (s, 3H, COOCH3); 2.30 (s, 3H, CH3); 4.75 (s, 
2H, COCH2); 8.10 (s, 1H, H at C-5), 8.29 (s, 1H, H at C-7). 
MS m/z: 390 (M
+). Anal. Calcd for C12H10N2O3Br2: C, 36.93; 
H, 2.59; N, 7.18. Found: C, 36.97; H, 2.62; N, 7.22. 
 6-Iodo-2-methyl-4-oxo-3(4H)-quinazolineacetic acid 
methyl ester (3d) Yield: 1.50 g (42%). mp: 146-148 °C. TLC 
Rf: 0.47. IR (KBr) cm
-1: 1740 (C=O), 1695 (C=O).
 1H-NMR 
(CDCl3) : 1.71 (s, 3H, COOCH3); 2.54 (s, 3H, CH3); 4.68 (s, 
2H, COCH2); 7.76 (d, 1H, H at C-8, J = 8.2 Hz); 8.05 (dd, 1H, 
H at C-7, J = 8.2 Hz, 2.1 Hz); 8.25 (d, 1H, H at C-5, J = 2.1 
Hz). MS m/z: 358 (M
+).  Anal. Calcd for C12H12N2O3I: C, 
40.23; H, 3.10; N, 7.82. Found: C, 40.00; H, 3.14; N, 7.67. 
 2-Ethyl-4-oxo-3(4H)-quinazolineacetic acid methyl es-
ter (3e) Yield: 2.09 g (85%). mp: 120-122 °C. TLC Rf: 0.61. 
IR (KBr) cm
-1: 1747 (C=O), 1678 (C=O).
 1H-NMR (CDCl3) 
: 1.41-1.45 (q, 3H, -CH2CH3, J = 8.7 Hz); 1.60 (s, 3H, COO-
CH3); 2.70-2.75 (t, 2H, CH2CH3, J = 8.69 Hz), 4.87 (s, 2H, 
COCH2); 8.0-8.5 (m, 4H, Ar-H). Anal. Calcd for C13H14N2O3: 
C, 63.39; H, 5.73; N, 11.38. Found: C, 63.42; H, 5.65; N, 
11.45. 
 6-Bromo-2-ethyl-4-oxo-3(4H)-quinazolineacetic acid 
methyl ester (3f) Yield: 1.46 g (45%). mp: 158-160 °C. TLC 
Rf: 0.58. IR (KBr) cm
-1: 1745 (C=O), 1691 (C=O). 
1H-NMR 
(CDCl3) : 1.53-1.57 (q, 3H, -CH2CH3, J = 8.5 Hz); 1.76 (s, 
3H, COOCH3); 2.79-2.82 (t, 2H, CH2CH3, J = 8.5 Hz), 4.87 (s, 
2H, COCH2); 7.72 (d, 1H, H at C-8, J = 8.1 Hz); 7.98 (dd, 1H, 
H at C-7, J = 8.1 Hz, 2.0 Hz); 8.13 (d, 1H, H at C-5, J = 2.1 
Hz). MS m/z: 325 (M
+). Anal. Calcd for C13H13N2O3Br: C, 
48.00; H, 4.03; N, 8.62. Found: C, 48.25; H, 3.90; N, 8.76. 
 6,8-Dibromo-2-ethyl-4-oxo-3(4H)-quinazolineacetic acid 
methyl ester (3g) Yield: 2.14 g (53%). mp: 145-147 °C. TLC 
Rf: 0.55. IR (KBr) cm
-1: 1743 (C=O), 1694 (C=O). 
1H-NMR 
(CDCl3) : 1.39-1.43 (q, 3H, -CH2CH3, J = 8.65 Hz); 1.53 (s, 
3H, COOCH3); 2.69-2.74 (t, 2H, CH2CH3, J = 8.65 Hz), 4.85 
(s, 2H, COCH2); 8.09-8.11 (s, 1H, H at C-5), 8.29-8.31 (s, 1H, 
H at C-7). MS m/z: 404 (M
+). Anal. Calcd for C13H12N2O3Br2: 
C, 38.62; H, 2.99; N, 6.93. Found: C, 38.64; H, 3.00; N, 6.89. 
 6-Iodo-2-ethyl-4-oxo-3(4H)-quinazolineacetic acid me-
thyl ester (3h) Yield: 1.45 g (39%). mp: 156-158 °C. TLC Rf: 
0.52. IR (KBr) cm
-1: 1740 (C=O), 1695 (C=O).
 1 H-NMR 
(CDCl3) : 1.49-1.54 (q, 3H, -CH2CH3, J = 8.53 Hz); 1.73 (s, 
3H, COOCH3); 2.74-2.78 (t, 2H, CH2CH3, J = 8.53 Hz), 4.77 
(s, 2H, COCH2); 7.71 (d, 1H, H at C-8, J = 8.1 Hz); 7.93 (dd, 
1H, H at C-7, J = 8.1 Hz, 2.0 Hz); 8.10 (d, 1H, H at C-5, J = 
2.1 Hz). MS m/z: 372 (M
+). Anal. Calcd for C13H13N2O3I: C, 
41.94; H, 3.52; N, 7.53. Found: C, 42.11; H, 3.53; N, 7.61. 
Synthesis of 2-Alkyl-4-Thioxo-3(4H)-Quinazolineacetic Acid 
Methyl Esters (4a-h) 
  Phosphorous pentasulphide (0.025 mol) was added to 2-
alkyl-4-oxo-3(4H)-quinazolineacetic acid methyl ester (3a-h; 
0.01 mol) in 1,4-dioxane (20 ml) and the reaction mixture was 
heated under reflux for 18-24 h. Excess solvent was distilled 
off under reduced pressure. The reaction mixture, on elution 
(column chromatography) with benzene, at first gave a resin-
ous, obnoxious red-colored liquid. Further, the product was 
eluted by gradually increasing the polarity of the solvent sys-
tem to benzene/chloroform/methanol (25:25:1 v/v). The prod-
uct was recrystallized from chloroform/benzene mixture (1:1 
v/v). The TLCs were recorded using chloroform/methanol (9:1 
v/v) as a mobile phase. 
 2-Methyl-4-thioxo-3(4H)-quinazolineacetic acid methyl 
ester (4a) Yield: 1.68 g (68%). mp: 158-60 °C. TLC Rf: 0.57. 
IR (KBr) cm
-1: 3345, 1682 (C=O), 1219. 
1H-NMR (DMSO-
d6) : 2.69 (s, 3H, CH3); 3.8 (s, 3H, COOCH3); 5.2 (s, 2H, 
COCH2); 7.6-7.8 (m, 4H, Ar-H). IR (KBr) cm
-1: 3348, 1680 
(C=O), 1220. MS m/z: 348 (M
+).  Anal. Calcd for 
C12H12N2O2S: C, 58.05; H, 4.88; N, 11.29. Found: C, 57.96; 
H, 4.82; N, 11.32. 
 6-Bromo-2-methyl-4-thioxo-3(4H)-quinazolineacetic acid 
methyl ester (4b) Yield: 2.35 g (72%). mp: 138-140 °C (Lit.
 
m.p. 138-140 °C) [19]. TLC Rf: 0.51. IR (KBr) cm
-1: 3330, 
1688 (C=O), 1225. 
1H-NMR (DMSO-d6) : 2.71 (s, 3H, CH3), 
3.7 (s, 3H, COOCH3), 5.3 (s, 2H, COCH2), 7.7 (d, 1H, Ar-H, J 
= 8.9 Hz,), 8.1 (dd, 1H, Ar-H, J = 8.34 Hz, 2.1 Hz), 8.64 (d, 
Ar-H,  J = 2.2). MS m/z: 327 (M
+).  Anal. Calcd for 
C12H11N2O2SBr: C, 44.04; H, 3.39; N, 8.57. Found: C, 44.25; 
H, 3.42; N, 8.49. 
 6,8-Dibromo-2-methyl-4-thioxo-3(4H)-quinazolineacetic 
acid methyl ester (4c) Yield: 3.17 g (78%). mp: 168-170 °C. 
TLC Rf: 0.50. IR (KBr) cm
-1: 3334, 1690 (C=O), 1228. 
1H-
NMR (CDCl3) : 1.77 (s, 3H, COOCH3); 2.48 (s, 3H, CH3); 
5.5 (s, 2H, COCH2); 8.21 (s, 1H, H at C-5), 8.39 (s, 1H, H at 
C-7). MS m/z: 406 (M
+). Anal. Calcd for C12H10N2O2SBr2: C, 
44.18; H, 3.09; N, 8.59. Found: C, 44.03; H, 3.20; N, 8.52. 
 6-Iodo-2-methyl-4-thioxo-3(4H)-quinazolineacetic acid 
methyl ester (4d) Yield: 2.80 g (75%). mp: 142-44 °C. TLC 
Rf: 0.47. IR (KBr) cm
-1: 3335, 1689 (C=O), 1222.
 1H-NMR 
(DMSO-d6) : 2.65 (s, 3H, CH3), 3.59 (s, 3H, COOCH3), 5.13 
(s, 2H, COCH2), 7.61 (d, 1H, H at C-8, J = 8.8 Hz,), 7.9 (dd, 
1H, H at C-7, J = 8.4 Hz, 2.2 Hz), 8.5 (d, H at C-5, J = 2.2). 
MS m/z: 374 (M
+). Anal. Calcd for C12H11N2O2SI: C, 38.51; 
H, 2.96; N, 7.49. Found: C, 38.44; H, 3.02; N, 7.49. 
 2-Ethyl-4-thioxo-3(4H)-quinazolineacetic acid methyl 
ester (4e) Yield: 1.83 g (70%). mp: 124-26 °C. TLC Rf: 0.59. 
IR (KBr) cm
-1: 3348, 1680 (C=O), 1220. 
1H-NMR (DMSO-
d6) : 1.28-1.31 (q, 3H, -CH2CH3, J = 7.42 Hz); 2.52 (s, 3H, Triazinoquinazolines as Bronchodilators  The Open Medicinal Chemistry Journal, 2008, Volume 2    105 
COOCH3); 2.67-2.71 (t, 2H, CH2CH3, J = 7.34 Hz), 4.67 (s, 
2H, COCH2); 7.6-7.8 (m, 4H, Ar-H). MS m/z: 348 (M
+, not 
recorded), 333, 299. Anal. Calcd for C13H14N2O2S: C, 59.52; 
H, 5.38; N, 10.69. Found: C, 59.50; H, 5.38; N, 10.78. 
 6-Bromo-2-ethyl-4-thioxo-3(4H)-quinazolineacetic acid 
methyl ester (4f) Yield: 2.48 g (73%). mp: 160-162 °C. TLC 
Rf: 0.57. IR (KBr) cm
-1: 3348, 1680 (C=O), 1220. 
1H-NMR 
(DMSO-d6) : 1.34-1.38 (q, 3H, -CH2CH3, J = 7.42 Hz); 2.67-
2.71 (t, 2H, CH2CH3, J = 7.34 Hz), 4.85 (s, 2H, COCH2); 7.52-
7.54 (d, 1H, H at C-8, J = 7.42 Hz), 7.79-7.81 (dd, 1H, H at C-
7, J = 8.3 Hz, 2.1 Hz); 8.34-8.35 (d, 1H, H at C-5, J = 2.1 Hz). 
MS m/z: 341 (M
+, not recorded), 326, 292, 263, 265, 253. 
Anal. Calcd for C13H13N2O2SBr: C, 45.61; H, 3.80; N, 8.18. 
Found: C, 45.50; H, 3.82; N, 7.83. 
 6,8-Dibromo-2-ethyl-4-thioxo-3(4H)-quinazolineacetic 
acid methyl ester (4g) Yield: 3.19 g (76%). mp: 154-156 
°C. TLC Rf: 0.54. IR (KBr) cm
-1: 3328, 1688 (C=O), 1225.
 
1H-NMR (DMSO-d6) : 1.44-1.47 (q, 3H, -CH2CH3, J = 7.42 
Hz); 2.70-2.73 (t, 2H, CH2CH3, J = 7.40 Hz), 5.15 (s, 2H, 
COCH2); 7.82 (s, 1H, H at C-7); 8.4 (d, 1H, H at C-5). MS 
m/z: 320 (M
+). Anal. Calcd for C13H12N2O2SBr2: C, 37.15; 
H, 2.88; N, 6.67. Found: C, 37.28; H, 2.82; N, 6.73. 
 6-Iodo-2-ethyl-4-thioxo-3(4H)-quinazolineacetic acid 
methyl ester (4h) Yield: 2.87 g (74%). mp: 168-170 °C. 
TLC Rf: 0.50. IR (KBr) cm
-1: 3337, 1685 (C=O), 1221. 
1H-
NMR (DMSO-d6)  : 1.31-1.35 (q, 3H, -CH2CH3, J = 7.39 
Hz); 2.61-2.65 (t, 2H, CH2CH3, J = 7.35 Hz), 4.68 (s, 2H, 
COCH2); 7.48-7.52 (d, 1H, H at C-8, J = 7.41 Hz), 7.75-7.79 
(dd, 1H, H at C-7, J = 8.2 Hz, 2.2 Hz); 8.33-8.34 (d, 1H, H at 
C-5,  J  = 2.2 Hz). MS m/z: 388 (M
+).  Anal. Calcd for 
C13H13N2O2SI: C, 40.21; H, 3.38; N, 7.22. Found: C, 40.00; 
H, 3.29; N, 7.23. 
Synthesis of 6-Alkyl-3-Oxo-3,4-Dihydro-2H-[1,2,4] Triazi-
no[4,3-c]Quinazolines (5a-h) 
  Hydrazine hydrate (99%; 0.02 mol) was added to methyl 
2-alkyl-4-thioxo-3(4H)-quinazolineacetic acid methyl ester 
(4a-h; 0.01 mol) in methanol (20 ml), and heated under reflux 
for 2-3 h. The progress of reaction was monitored by using a 
lead acetate paper, which turns black and also with TLC using 
chloroform/methanol (88:12 v/v) as a mobile phase. The mix-
ture was cooled and the precipitated product was filtered off, 
washed with a little cold ethanol, dried, and recrystallized 
from ethanol (95%). Using the above procedure, eight 6-alkyl-
3-oxo-3,4-dihydro-2H-[1,2,4]triazino[4,3-c]quinazolines (5a-
h) were synthesized and characterized. 
 6-Methyl-3-oxo-3,4-dihydro-2H-[1,2,4]triazino[4,3-c]qui-
nazoline (5a) Yield: 1.39 g (65%). mp: 298-300 °C (Lit. 
298-300 °C) [18]. TLC Rf: 0.51. IR (KBr) cm
-1: 3420-3460 
(br, OH), 3280 (NH), 1681 (C=O), 1589 (C=N). 
1H-NMR 
(DMSO-d6) : 2.42 (s, 3H, CH3); 4.72 (s, 2H, COCH2); 7.10-
7.65 (m, 3H, H at C-8,9,10); 7.81-8.05 (d, 1H, H at C-11, J 
= 3.82 Hz); 11.00 (s, 1H, NH). MS m/z: 214 (M
+, not recor-
ded), 188, 186. Anal. Calcd for C11H10N4O: C, 61.67; H, 
4.71; N, 26.15. Found: C, 61.60; H, 4.69; N, 26.12. 
 10-Bromo-6-methyl-3-oxo-3,4-dihydro-2H-[1,2,4]triazi-
no[4,3-c]quinazoline (5b) Yield: 1.96 g (67%). mp: 228-230 
°C. TLC Rf: 0.48. IR (KBr) cm
-1: 3415-3460 (br, OH), 3275 
(NH), 1664 (C=O), 1586 (C=N). 
1H-NMR (DMSO-d6) : 2.58 
(s, 3H, CH3); 5.82 (s, 2H, COCH2); 7.35-7.45 (d, 1H, H at C-
8, J = 3.86 Hz), 8.04-8.06 (m, 1H, H at C-9); 8.34 (s, 1H, H at 
C-11). MS m/z: 293 (M
+), 255, 253, 237, 223, 197, 196, 195, 
182, 170, 155. Anal. Calcd for C11H9N4BrO: C, 45.07; H, 
3.10; N, 19.11. Found: C, 45.22; H, 3.15; N, 19.12. 
 8,10-Dibromo-6-methyl-3-oxo-3,4-dihydro-2H-[1,2,4]tri-
azino[4,3-c]quinazoline(5c) Yield: 2.53 g (68%). mp: 184-186 
°C. TLC Rf: 0.47. IR (KBr) cm
-1: 3430-3480 (br, OH), 3290 
(NH), 1664 (C=O), 1586 (C=N). 
1H-NMR (DMSO-d6) : 2.60 
(s, 3H, -CH3); 5.87 (s, 2H, COCH2); 8.18 (s, 1H, H at C-9); 
8.30 (s, 1H, H at C-11). MS m/z: 372 (M
+), 334, 332, 316, 
302, 286, 285, 284. Anal. Calcd for C11H8N4Br2O: C, 35.52; 
H, 2.18; N, 15.06. Found: C, 35.42; H, 2.16; N, 14.92. 
 10-Iodo-6-methyl-3-oxo-3,4-dihydro-2H-[1,2,4]triazino[ 
4,3-c]quinazoline (5d) Yield: 2.27 g (67%). mp: 184-186 °C. 
TLC Rf: 0.45. ). IR (KBr) cm
-1: 3415-3460 (br, OH), 3287 
(NH), 1664 (C=O), 1599 (C=N). 
1H-NMR (DMSO-d6) : 2.56 
(s, 3H, CH3); 5.81 (s, 2H, COCH2); 7.37-7.40 (d, 1H, H at C-
8, J = 7.84 Hz), 8.02-8.05 (m, 1H, H at C-9); 8.36 (s, 1H, H at 
C-11). MS m/z: 340 (M
+, not recorded), 301, 300, 285, 258, 
256, 242, 231. Anal. Calcd for C11H9N4IO: C, 38.82; H, 2.64; 
N, 16.47. Found: C, 38.04; H, 2.63; N, 16.02. 
 6-Ethyl-3-oxo-3,4-dihydro-2H-[1,2,4]triazino[4,3-c]qui-
nazoline (5e) Yield: 1.41 g (62%). mp: 260-262 °C. TLC Rf: 
0.55. IR (KBr) cm
-1: 3425-3465 (br, OH), 3278 (NH), 1680 
(C=O), 1585 (C=N). 
1H-NMR (DMSO-d6)  : 1.23-1.26 (q, 
3H, -CH2CH3 J = 8.72 Hz); 2.73-2.78 (t, 2H, CH2CH3 J = 8.65 
Hz), 4.72 (s, 2H, COCH2); 7.46-7.81 (m, 1H, H at C-8, 9, 10); 
8.06-8.08 (d, 1H, H at C-11, J = 3.80 Hz); 9.39 (s, 1H, -NH). 
MS m/z: 228 (M
+, not recorded), 215, 188, 187, 173, 158, 130. 
Anal. Calcd for C12H12N4O: C, 63.15; H, 5.26; N, 24.56. 
Found: C, 62.83; H, 5.69; N, 23.68. 
 10-Bromo-6-ethyl-3-oxo-3,4-dihydro-2H-[1,2,4]triazino 
[4,3-c]quinazoline (5f) Yield: 2.03 g (66%). mp: 165-167 °C. 
TLC Rf: 0.51. IR (KBr) cm
-1: 3420-3465 (br, OH), 3270 
(NH), 1661 (C=O), 1584 (C=N). 
1H-NMR (DMSO-d6) 
: 1.24-1.28 (q, 3H, -CH2CH3, J = 7.78 Hz); 2.91-2.97 (t, 2H, 
CH2CH3, J = 7.80 Hz), 5.76 (s, 2H, COCH2); 7.57-7.92 (m, 
1H, H at C-8, 9); 8.17-8.19 (d, 1H, H at C-11, J = 3.98 Hz). 
MS m/z: 307 (M
+), 269, 267, 251, 225, 224, 223, 210, 197, 
183, 169, 155. Anal. Calcd for C12H11N4BrO: C, 46.90; H, 
4.51; N, 18.24. Found: C, 47.28; H, 4.58; N, 18.49. 
 8,10-Dibromo-6-ethyl-3-oxo-3,4-dihydro-2H-[1,2,4]tri-
azino[4,3-c]quinazoline (5g) Yield: 2.66 g (69%). mp: 182-
184 °C. TLC Rf: 0.49. IR (KBr) cm
-1: 3423-3467 (br, OH), 
3272 (NH), 1659 (C=O), 1579 (C=N). 
1H-NMR (DMSO-d6) 
: 1.281.30 (t, 3H, -CH2CH3, J = 7.80 Hz); 2.95-3.00 (q, 2H, 
-CH2CH3, J = 7.82 Hz), 5.80 (s, 2H, COCH2); 8.18-8.19 (s, 
1H, H at C-9); 8.31-8.32 (s, 1H, H at C-11); 9.40 (s, 1H, -NH). 
MS m/z: 386 (M
+), 348, 346, 330, 316, 300, 299, 298. Anal. 
Calcd for C12H10N4Br2O C, 37.34; H, 2.61; N, 14.51. Found: 
C, 37.40; H, 2.73; N, 14.36. 
 10-Iodo-6-ethyl-3-oxo-3,4-dihydro-2H-[1,2,4]triazino[4,3-
c] quinazolines (5h) Yield: 2.37 g (67%). mp: 172-174 °C. 106    The Open Medicinal Chemistry Journal, 2008, Volume 2  Kombu et al. 
TLC Rf: 0.47. IR (KBr) cm
-1: 3413-3462 (br, OH), 3285 
(NH), 1662 (C=O), 1600 (C=N). 
1H-NMR (DMSO-d6) 
: 1.361.40 (t, 3H, -CH2CH3, J = 7.80 Hz); 3.00-3.07 (q, 2H, 
CH2CH3, J = 7.81 Hz), 4.85 (s, 2H, COCH2); 7.40-7.86 (m, 
1H, H at C-8, 9); 8.51-8.58 (s, 1H, H at C-11, J = 3.86 Hz); 
9.42 (s, 1H, -NH). MS m/z: 354 (M
+, not recorded), 314, 315, 
299, 272, 270, 256, 245. Anal. Calcd for C12H11N4IO: C, 
40.67; H, 3.11; N, 15.85. Found: C, 40.74; H, 3.28; N, 16.10. 
Synthesis of 2-Aryl-4-Oxo-3(4H)-Quinazolineacetic Acid 
Hydrazides (7a-h) 
  Thionyl chloride (5 ml) was added to 2-aryl-4-oxo-3(4H)-
quinazolineacetic acid (2i-p; 0.01 mol), and heated under re-
flux on a water bath for 1 h. The excess thionyl chloride was 
removed under reduced pressure. Without further purification, 
the obtained acidchloride (6a-h) was added to dry pyridine (10 
ml) and cooled (0 °C) using a freezing mixture. To this solu-
tion, hydrazine hydrate (99%) (0.025 mol) was added at once 
with vigorous stirring. The mixture was stirred for one hour 
and poured onto crushed ice with continuous stirring. The 
obtained product was filtered-off, washed with water, dried 
and recrystallized from ethanol (95%) to yield crystalline 
solid. Following the above procedure, eight acid hydrazides 
(7a-h)  were synthesized. For TLC, chloroform/ethylacetate 
(1:1 v/v) was used as mobile phase. 
 2-Phenyl-4-oxo-3(4H)-quinazolineacetic acid hydrazide 
(7a) Yield: 2.8 g (96%). mp: 242-245 °C (d) (Lit. m.p. 245 
°C) [17]. TLC Rf: 0.62. IR (KBr) cm
-1: 3319 (NH), 1650 
(C=O), 1604 (C=O), 1529 (C=N). 
1H-NMR (CDCl3) : 4.29 
(m, 3H, NHNH2); 5.08 (s, 2H, COCH2); 7.44-8.16 (m, 9H, Ar-
H). MS m/z: 294 (M
+). Anal. Calcd for C16H14N4O2: C, 65.28; 
H, 4.80; N, 19.04. Found: C, 65.33; H, 4.72; N, 19.10. 
 2-(4-Methylphenyl)-4-oxo-3(4H)-quinazolineacetic acid 
hydrazide (7b) Yield: 2.52 g (82%). mp: 162-4 °C. TLC Rf: 
0.65. IR (KBr) cm
-1: 3325 (NH), 1640 (C=O), 1600 (C=O), 
1525 (C=N).
 1H-NMR (CDCl3) : 2.3 (s, 3H, CH3); 4.35 (m, 
3H, NHNH2); 4.98 (s, 2H, COCH2); 7.50-8.15 (m, 8H, Ar-H). 
MS m/z: 308 (M
+). Anal. Calcd for C17H16N4O2: C, 66.21; H, 
5.23; N, 18.18. Found: C, 66.23; H, 5.26; N, 18.21. 
 2-(2-Methoxyphenyl)-4-oxo-3(4H)-quinazolineacetic acid 
hydrazide (7c) Yield: 2.82 g (87%). mp: 150-152 °C. TLC 
Rf: 0.49. IR (KBr) cm
-1: 3328 (NH), 1644 (C=O), 1608 
(C=O), 1526 (C=N).
 1H-NMR (CDCl3) : 3.7 (s, 3H, OCH3); 
4.35 (m, 3H, NHNH2); 4.95 (s, 2H, COCH2); 7.62-8.23 (m, 
8H, Ar-H). MS m/z: 324 (M
+). Anal. Calcd for C17H16N4O3: 
C, 66.94; H, 4.98; N, 17.28. Found: C, 67.17; H, 5.03; N, 
17.32. 
 2-(3-Methoxyphenyl)-4-oxo-3(4H)-quinazolineacetic acid 
hydrazide (7d) Yield: 2.65 g (85%). mp: 160-162 °C. TLC 
Rf: 0.53. IR (KBr) cm
-1: 3326 (NH), 1639 (C=O), 1607 
(C=O), 1523 (C=N).
 1H-NMR (CDCl3) : 3.5 (s, 3H, OCH3); 
4.42 (m, 3H, NHNH2); 5.02 (s, 2H, COCH2); 7.67-8.25 (m, 
8H, Ar-H). MS m/z: 324 (M
+). Anal. Calcd for C17H16N4O3: 
C, 66.94; H, 4.98; N, 17.28. Found: C, 66.80; H, 4.94; N, 
17.16. 
 2-(4-Methoxyphenyl)-4-oxo-3(4H)-quinazolineacetic acid 
hydrazide (7e) Yield: 2.65 g (85%). mp: 174-176 °C. TLC 
Rf: 0.51. IR (KBr) cm
-1: 3328 (NH), 1639 (C=O), 1597 
(C=O), 1527 (C=N).
 1H-NMR (CDCl3) : 3.8 (s, 3H, OCH3); 
4.61 (m, 3H, NHNH2); 5.15 (s, 2H, COCH2); 7.70-8.23 (m, 
8H, Ar-H). MS m/z: 324 (M
+). Anal. Calcd for C17H16N4O3: 
C, 66.94; H, 4.98; N, 17.28. Found: C, 66.98; H, 4.87; N, 
17.19. 
 2-(4-Bromophenyl)-4-oxo-3(4H)-quinazolineacetic acid 
hydrazide (7f) Yield: 3.10 g (83%). mp: 168-169 °C. TLC Rf: 
0.55. IR (KBr) cm
-1: 3326 (NH), 1639 (C=O), 1607 (C=O), 
1523 (C=N). 
1H-NMR (CDCl3) : 4.70 (m, 3H, NHNH2); 5.23 
(s, 2H, COCH2); 7.68-8.19 (m, 8H, Ar-H). MS m/z: 373 (M
+). 
Anal. Calcd for C16H13N4O2Br: C, 51.47; H, 3.51; N, 15.02. 
Found: C, 51.48; H, 3.63; N, 15.05. 
 2-(4-Nitrophenyl)-4-oxo-3(4H)-quinazolineacetic acid 
hydrazide (7g) Yield: 2.64 g (78%). mp: 239-241 °C. TLC 
Rf: 0.47. IR (KBr) cm
-1: 3336 (NH), 1629 (C=O), 1627 
(C=O), 1573 (C=N). 
1H-NMR (CDCl3) : 4.78 (m, 3H, NH-
NH2); 5.30 (s, 2H, COCH2); 7.72-8.31 (m, 8H, Ar-H). MS 
m/z: 339 (M
+). Anal. Calcd for C16H13N5O4: C, 56.62; H, 3.86; 
N, 20.65. Found: C, 56.46; H, 3.86; N, 20.54. 
 2-(3-Chlorophenyl)-4-oxo-3(4H)-quinazolineacetic acid 
hydrazide (7h) Yield: 2.32 g (74%). mp: 170-172 °C. TLC 
Rf: 0.45. IR (KBr) cm
-1: 3371 (NH), 1650 (C=O), 1604 
(C=O), 1529 (C=N).
 1H-NMR (CDCl3) : 4.52 (m, 3H, NH-
NH2); 5.11 (s, 2H, COCH2); 7.60-8.19 (m, 8H, Ar-H). MS 
m/z: 329 (M
+). Anal. Calcd for C16H13N4O2Cl: C, 58.44; H, 
3.99; N, 17.05. Found: C, 58.47; H, 3.96; N, 17.10. 
Synthesis of 6-Aryl-3-Oxo-3,4-Dihydro-2H-[1,2,4]Triazino 
[4,3-c]Quinazolines (8a-h) 
  On an oil bath, 2-aryl-4-oxo-3(4H)-quinazolineacetic acid 
hydrazide (7a-h; 0.01 mol) was fused at 240-250 °C for one 
hour. The obtained product was recrystallized from an ethanol 
(95%)/chloroform mixture (40:10 v/v) to yield a pure product. 
Eight 6-aryl-3-oxo-3,4-dihydro-2H-[1,2,4]triazino[4,3-c]qui-
nazolines (8a-h) were synthesized and characterized using this 
procedure. The TLCs were recorded using chloroform/ 
methanol (19:1 v/v) as a mobile phase. 
 6-Phenyl-3-oxo-3,4-dihydro-2H-[1,2,4]triazino[4,3-c]qui- 
nazoline (8a) Yield: 1.39 g (65%). mp: 176-178 °C. TLC Rf: 
0.72. IR (KBr) cm
-1: 3455-3505 (br, OH), 3307 (NH), 1663 
(C=O), 1592 (C=N). 
1H-NMR (CDCl3) : 4.99 (s, 2H, COCH2); 
7.48-7.78 (m, 9H, Ar-H); 8.30 (s, 1H, -NH). 
13C-NMR 
(CDCl3) :  77.25 (C-4), 120.14 (C-8), 126.6 (C-2' and C-6'), 
127.01 (C-11a), 127.92 (C-10 and C-11), 128.19 (C-3' and C-
5'), 129.22 (C-4'), 130.21 (C-9), 134.09 (C-1'), 134.44 (C-3), 
147.04 (C-7a), 154.55 (C-12), 161.56 (C-6). MS m/z: 276 
(M
+, not recorded), 238, 237, 222, 221, 208,180. Anal. Calcd 
for C15H10N4O: C, 68.69; H, 3.84; N, 21.36. Found: C, 68.45; 
H, 4.02; N, 21.46. 
 6-(4-methylphenyl)-3-oxo-3,4-dihydro-2H-[1,2,4]triazino[ 
4,3-c]quinazoline (8b) Yield: 1.94 g (67%). mp: 148-150 °C. 
TLC Rf: 0.65. IR (KBr) cm
-1: 3450-3503 (br, OH), 3300 
(NH), 1668 (C=O), 1598 (C=N). 
1H-NMR (CDCl3) : 2.25 (s, 
3H, PhCH3), 4.98 (s, 2H, COCH2); 7.52-7.84 (m, 8H, Ar-H); 
8.35 (s, 1H, -NH). MS m/z: 290 (M
+, not recorded), 252, 251, Triazinoquinazolines as Bronchodilators  The Open Medicinal Chemistry Journal, 2008, Volume 2    107 
236, 235, 222, 194. Anal. Calcd for C16H12N4O: C, 69.55; H, 
4.38; N, 20.28. Found: C, 69.55; H, 4.22; N, 20.26. 
 6-(2-methoxyphenyl)-3-oxo-3,4-dihydro-2H-[1,2,4]tria-
zino[4,3-c]quinazoline (8c) Yield: 1.77 g (58%). mp: 132-135 
°C. TLC Rf: 0.70. IR (KBr) cm
-1: 3463-3515 (br, OH), 3311 
(NH), 1665 (C=O), 1595 (C=N).
 1H-NMR (CDCl3) : 3.80 (s, 
3H, -OCH3), 5.04 (s, 2H, COCH2); 7.13-7.53 (m, 8H, Ar-H); 
8.39 (s, 1H, -NH). MS m/z: 306 (M
+, not recorded), 266, 253. 
Anal. Calcd for C17H14N4O2: C, 66.69; H, 4.60; N, 18.30. 
Found: C, 67.28; H, 4.35; N, 18.26. 
 6-(3-methoxyphenyl)-3-oxo-3,4-dihydro-2H-[1,2,4]triazi- 
no[4,3-c]quinazoline (8d) Yield: 2.38 g (78%). mp: 150-152 
°C. TLC Rf: 0.70. IR (KBr) cm
-1: 3452-3504 (br, OH), 3310 
(NH), 1646 (C=O), 1580 (C=N). 
1H-NMR (CDCl3) : 3.86 (s, 
3H, -OCH3), 5.02 (s, 2H, COCH2); 7.03-7.51 (m, 8H, Ar-H); 
8.32 (s, 1H, -NH). 
13C-NMR (CDCl3)  :   55.45 (-OCH3), 
78.5 (C-4), 114.64 (C-2'), 116.01 (C-4'), 120.16 (C-6'), 121.14 
(C-8), 126.59 (11a), 127.05 (C-10 and C-11), 127.92 (C-5'), 
129.37 (C-9), 134.43 (C-1'), 135.24 (C-3), 146.96 (C-7a), 
154.26 (C-12), 159.38 (C-3'), 161.41 (C-6). MS m/z: 306 (M
+, 
not recorded), 266, 253. Anal. Calcd for C17H14N4O2: C, 
66.69; H, 4.60; N, 18.30. Found: C, 67.25; H, 5.05; N, 18.56. 
 6-(4-Methoxyphenyl)-3-oxo-3,4-dihydro-2H-[1,2,4]triazi-
no[4,3-c]quinazoline (8e) Yield: 2.17 g (71%). mp: 162-164 
°C. TLC Rf: 0.69. IR (KBr) cm
-1: 3443-3509 (br, OH), 3313 
(NH), 1649 (C=O), 1582 (C=N). 
1H-NMR (CDCl3) : 3.88 (s, 
3H, -OCH3), 5.04 (s, 2H, COCH2); 7.02-7.54 (m, 8H, Ar-H); 
8.38 (s, 1H, -NH). MS m/z: 306 (M
+), 266, 253. Anal. Calcd 
for C17H14N4O2: C, 66.69; H, 4.60; N, 18.30. Found: C, 62.35; 
H, 4.58; N, 18.49. 
 6-(4-Bromophenyl)-3-oxo-3,4-dihydro-2H-[1,2,4]triazi-
no[4,3-c]quinazoline (8f) Yield: 2.66 g (75%). mp: 155-156 
°C. TLC Rf: 0.74. IR (KBr) cm
-1: 3453-3499 (br, OH), 3301 
(NH), 1657 (C=O), 1585 (C=N). 
1H-NMR (CDCl3) : 4.98 (s, 
2H, COCH2); 7.22-8.42 (m, 8H, Ar-H) 8.55 (s, 1H, -NH). MS 
m/z: 355 (M
+, not recorded), 317, 302. Anal. Calcd for 
C15H9N4BrO: C, 52.81; H, 2.66; N, 16.42 Found: C, 52.69; H, 
2.70; N, 16.61. 
 6-(4-Nitrophenyl)-3-oxo-3,4-dihydro-2H-[1,2,4]triazino[ 
4,3-c]quinazoline (8g) Yield: 2.72 g (85%). mp: 223-225 °C. 
TLC Rf: 0.45. IR (KBr) cm
-1: 3415-3450 (br, OH), 3304 
(NH), 1679 (C=O), 1550 (C=N). 
1H-NMR (CDCl3) : 4.95 (s, 
2H, COCH2); 7.28-8.32 (m, 8H, Ar-H) 8.45 (s, 1H, -NH). MS 
m/z: 321 (M
+, not recorded), 283, 268, 253, 238. Anal. Calcd 
for C15H9N5O3: C, 58.64; H, 2.95; N, 22.79 Found: C, 58.95; 
H, 3.08; N, 22.87. 
 6-[3-Chlorophenyl]-3-oxo-3,4-dihydro-2H-[1,2,4]triazino[ 
4,3-c]quinazoline (8h) Yield: 2.52 g (81%). mp: 163-165 °C. 
TLC Rf: 0.43. IR (KBr) cm
-1: 3425-3470 (br, OH), 3309 
(NH), 1663 (C=O), 1584 (N=H). 
1H-NMR (CDCl3) : 4.94 (s, 
2H,  COCH2); 7.24-8.31 (m, 8H, Ar-H). 
13C-NMR (CDCl3) 
: 77 (C-4), 120.23(C-8), 126.66 (C-6'), 127.32 (C-2'), 127.61 
(C-11a), 127.96 (C-10 and C-11), 129.36 (C-5'), 129.59 (C-4'), 
130.27 (C-9), 134.16 (C-3'), 134.61 (C-1'), 135.69 (C-3), 
146.88 (C-7a), 153.34 (C-12), 161.62 (C-6). MS m/z: 311 
(M
+, not recorded), 273, 258. Anal. Calcd for C16H11N4OCl: C, 
61.83; H, 3.54; N, 18.04. Found: C, 61.77; H, 3.72; N, 18.27. 
Pharmacology 
General Methods 
  Heartly guinea pigs of either sex (7-8 weeks old, 250-
300g) were obtained from National Institute of Nutrition 
(Hyderabad, India), and housed in wire-mesh cages in a re-
stricted access room, under constant conditions (23 ± 2 °C, 
12 h light) for 3-4 days before the experiments. The animals 
were fed standard lab pallets (Hindustan Lever Ltd., Mum-
bai) and purified water ad libitum. Prior to the studies, the 
animals were fasted for 24 h (i.e., they were deprived of food 
but maintained on purified water). All the animal experi-
ments were carried out according to internationally valid 
guidelines, with approval from the ‘Institutional Animal Eth-
ics Committee’ of the university. 
Bronchodilator Activity: Protection Against Histamine-
Induced Bronchospasm on Conscious Guinea Pigs (In 
Vivo Model) 
  The bronchodilator activity was carried out for all the 
title compounds by in vivo method. For in vivo activity, a 
histamine chamber method [20] was used. Aminophylline 
was used as standard bronchodilator. 
  A modification of the technique of van Arman et al, was 
used. A group of five albino guinea pigs of either sex (250-
300 g) were fasted for 24 h. The test compounds were ad-
ministered intraperitoneally at a dose of 50 μM/kilo body 
weight (kbw) and challenged with a histamine aerosol (0.2% 
aqueous solution of histamine acid phosphate in a 
Vaponephrin Pocket Nebulizer, Inco Instruments, Ambala, 
India) sprayed into a closed transparent cage. The respiratory 
status, reflecting the increasing degree of bronchoconstric-
tion, was recorded. The observations were made for 30 min-
utes. The time of the onset of convulsions was recorded. 
Animals remaining stable (appearing normal, without in-
creased respiratory rate and convulsions) for more than 6 
minutes were considered protected against histamine-
induced bronchospasm. An intraperitoneal injection of 
chlorpheneramine maleate at a dose of 25 mg/kbw was given 
for the recovery of the test animals. Aminophylline (50 
μM/kbw) was used as a standard bronchodilator for compari-
son. The IC50 values have been expressed in terms of per-
centage protection (Table 1). 
RESULTS AND DISCUSSIONS 
Chemistry 
  A literature survey revealed different procedures for the 
construction of 1,2,4-triazinoquinazolines, using thermal 
cyclizations [21], cyclocondensation [22],
 dehydro cycliza-
tion [23] and some different synthetic methodologies 
[24,25].
  The synthesis of 6-alkyl-1,2,4-triazino[4,3-
c]quinazolines 5a-h has been effected as depicted in (Fig. 2) 
and that of 6-aryl-1,2,4-triazino[4,3-c]quinazolines  8a-h in 
(Fig.  3). 1,2,4-triazino[4,3-c]quinazolines were synthesized 
by condensing benzoxazinones 1a-h  with glycine in pres-
ence of 1-methoxy-2-(2-methoxyethoxy)ethane or aqueous 108    The Open Medicinal Chemistry Journal, 2008, Volume 2  Kombu et al. 
pyridine to give substituted quinazolineacetic acids 2a-h. 
The IR spectra of Compound 2 showed characterisitic broad 
carboxylic acid peak at around 3410 cm
-1. The incorporation 
of glycine was further confirmed by the NMR spectra with a 
peak at 4.6, corresponding to CH2-C=O group and by mass 
spectra. 
  Upon confirmation of Compound 2 spectral data, they 
were converted to their corresponding esters 3a-h. Com-
pound 3 were confirmed by the disappearance of the broad 
carboxylic acid peak in the IR spectra and by appearance of a 
methyl group as a singlet at  1.7 ppm in 
1H NMR spetra. 
The mass spectra showed the molecular ion peak. Compound 
3, by heating under reflux in phosphorous pentasulphide 
were converted to 4a-h their thioxo derivative, confirmed by 
the spectral data. Upon cyclization with hydrazine hydrate, 
compound  4  yielded compound 5a-h  ranging from 65 to 
69%. In the IR spectrum, the disappearance of C=S peak in 
compound 4a-h  showed the completion of the reaction to 
give compound 5a-h. 
 Alternatively  2 were converted to their corresponding 
acid chlorides 6 in presence of thionyl chloride. Acid chlo-
ride 6, without further purificaition, on treatment with hydra-
zine hydrate gave the hydrazides 7a-h. The hydrazides 
showed a characteristic multiplet at  4.7 ppm in 
1H NMR 
spectra. Compound 7, in turn cyclized in ethanol gave 6-
aryl-1,2,4-triazino[4,3-c]quinazolines 8a-h. The yields were 
58-85%. Thus the present route, being advantageous in sim-
ple reaction conditions and easy work-up procedures, has 
resulted in improved yields. 
  The title compounds 5 and 8 showed a peak at around 
3480 cm
-1 as a broad weak signal corresponding to the 
tautomeric carbonyl amido group in their IR spectra. At 
around 3200-3300 cm
-1 a peak appeard for secondary amino 
group and at 1650 cm
-1 a peak appeard for amide carbonyl 
group. This further revealed the formation of the expected 
product. The 
1H NMR spectrum showed a singlet at  4.86 
ppm corresponding to methylene protons at C-4. A doublet 
of doublet appeared at  7.78-7.82 ppm corresponding to the 
proton at C-9. Also, two doublets appeared at  7.53-7.56 
ppm and  8.36 ppm, corresponding to two protons at C-8 
and C-11 respectively for unsubstituted triazinoquinazolines. 
The NH proton could be recorded below  9 ppm. In CMR 
spectrum, characteristic peaks were observed to due keto-
enol tautomerism of –COCH2- group. The signal of the terti-
ary carbon of HO-C(NH)=CH- appeared at 147  ppm and of 
secondary carbon appeared at 77  ppm. 
  Though the mass spectrum [EI-MS] did not show a mol-
cular ion peak (M
+) the fragmentation pattern is characteris-
tic to its structure. The loss of carbon suboxide (C2O) was 
found to be a common path in triazino[4,3-c]quinazolines. 
The fragmentation pattern of 10-bromo-6-methyl-3-oxo-3,4-
dihydro-2H-[1,2,4]triazino[4,3-c]quinazoline (5a) is ex-
plained. The molecular ion of compound 5a was recorded at 
m/z 307 with a relative abundance of 1%. On losing carbon 
Table 1.  Bronchodilatory Activity  (In Vivo) of 6-Alkyl/Aryl-3-Oxo-3,4-Dihydro-2H-[1,2,4]Triazino[4,3-c]Quinazolines (5a-h and 
8a-h) 
 
Compound
a  X X’  R  Mean ± SD Time of Onset of Convulsions (in Sec.) (n = 5)  % Protection
b 
5a  H H  CH3  338 ± 158  39.77 
5b  Br H  CH3  1800 ± 0
c  88.70 
5c  Br Br  CH3  1763 ± 53  88.47 
5d  I H  CH3  1229 ± 228  83.45 
5e  H H  C2H5  296 ± 61  31.30 
5f  Br H  C2H5  1688 ± 250  87.95 
5g  Br Br  C2H5  1700 ± 224  88.04 
5h  I H  C2H5  1686 ± 91  87.94 
8a  H H  -C6H5  991 ± 70  79.48 
8b  H H  4-CH3-C6H4  626 ± 58  67.54 
8c  H H  2-OCH3-C6H4  897 ± 52  77.34 
8d  H H  3-OCH3-C6H4  721 ± 51  71.79 
8f  H H  4-Br-C6H4  833 ± 100  75.58 
8g  H H  4-NO2-C6H4  960 ± 181  78.81 
Aminophylline       1665 ± 147  87.79 
Control       ± 50   
a) Dose = 50 μM/kbw; b) Percentage protection = [1-T1/T2] x 100, Where, T1 = mean time of onset of convulsions (in Sec.) of control, T2 = mean time of onset of convulsions (in 
Sec.) of drug treatment with respect to standard (aminophylline); c) All five guinea pigs were stable above 1800 Sec. Triazinoquinazolines as Bronchodilators  The Open Medicinal Chemistry Journal, 2008, Volume 2    109 
suboxide (C2O), molecular ion produced a base peak at m/z 
267. By losing an amino group, the base peak yielded m/z 
251 with a relative abundance of 37%. Further, on losing a 
cyano group and two protons sequantially produced ions at 
m/z 225 (14%), m/z 224 (20%) and m/z 223 (15%). The ion 
m/z 223 on lose of cyanide radical gave a peak at m/z 197 
with a relative abundance of 68%. Further m/z 197, on sub-
sequential losses of two methylenes and a nitrogen radical 
produced ions m/z 183 (13%), m/z 169 (13%) and bromo 
benzine radical (m/z 155; 15%) respectively. 
Pharmacology 
Protection Against Histamine-Induced Bronchospasm on 
Conscious Guinea Pigs (In Vivo Model) 
  Sixteen compounds of triazino-fused quinazolines con-
taining both alkyl and aryl substitutions with halo substitu-
tions on the quinazoline ring were evaluated for bronchodila-
tor activity at the dose level of 50 μM/kbw based on the re-
ported methods [20]. Most of the compounds were found to 
exhibit bronchodilator activity in guinea pig (in vivo) mod-
els. Percentage protection data showed that all the test com-
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Fig. (2). Synthesis of 6-alkyl-1,2,4-triazino[4,3-c]quinazolines 5(a-h). 
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pounds of series have shown protection in the range of 31-
89%. 
  To find out the statistical significance between data, a 
one-way ANOVA (Dunnett’s test) was performed. The com-
pounds 8e and 8h were found to be inactive. Structure activ-
ity relationship (SAR) studies indicated that the alkyl and 
aryl substitutions at 6
th position of triazino[4,3-c]quinazo-
lines and substituents at 8
th and 10
th position of triazino-
quinazoline ring found to exert varied biological activity. 
Among the 6-aryl-triazino[4,3-c]quinazolines, compounds 
8a, c  and g (79.48, 77.34 and 78.81% protection respec-
tively) were found to be comparably potent to the standard 
(aminophylline). Among the 6-alkyl-triazino[4,3-c]quinazo-
lines, 6-ethyl derivatives were less potent than their corre-
sponding methyl analogues. 8, 10-halo substitution increased 
their activity levels compared to unsubstituted compounds, 
and found to be equipotent or more potent than aminophyl-
line. 
  All the test compounds have exhibited bronchodilatory 
activity in in vivo evaluation and most of the compounds 
were found to be equipotent when compared with the refer-
ence compound. The design of the title compounds, as indi-
cated, was done on the basis of xanthine skeleton. Although 
lacking a xanthine nucleus in their structures, these com-
pounds exhibited bronchodilatory effects similar to xanthine 
derivatives. The results of SAR studies show identical fea-
tures in both the series of the title compounds. The presence 
of electron withdrawing groups enhanced the potency, in 
general. Hence, bromo-substituted compounds were the most 
potent in alkyl series and a nitro substitution on phenyl ring 
seems to increase the activity. This reveals that the incorpo-
ration of an aryl ring with halo substitution, to the theophyl-
line bioisostere increases its potency. 
CONCLUSION 
  In conclusion, we have designed and synthesized a set of 
novel 6-alkyl/aryl triazino[4,3-c] quinazolines as possible 
bronchodilators. Although they lack a xanthine nucleus in 
their structure, the quinazolines exhibited bronchodilatory 
effects similar to xanthine derivatives. All the test com-
pounds exhibited bronchodilatory activity in in vivo evalua-
tion. Further studies are in progress to determine the exact 
mechanism of these molecules, and to explore other possible 
isosteres. 
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